Interstitial Cystitis (IC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Interstitial cystitis (IC), or Bladder pain syndrome (BPS), is a persistent condition causing painful urinary symptoms. It's characterized by ongoing discomfort (pain, pressure, bladder spasms) in the pelvic region, lasting over six months, often worsening during bladder filling. Limited bladder capacity is common but not obligatory. Frequent urination, nighttime urination, and urgency are frequently associated with IC. There are two distinct types: Hunner-Type and Non-Hunner-Type IC. The exact cause of this disorder remains uncertain, likely involving various factors such as changes in bladder lining permeability, prior infections (including bacterial cystitis history), hormonal, vascular, or neurological abnormalities, trauma, inflammation, autoimmune diseases, as well as risk factors like pelvic surgery, alterations in the microbiome, reduced microcirculation, histamine sensitivity, pelvic floor dysfunction, endometriosis, genetic factors, and psychological factors. Diagnosing IC relies on patient history, questionnaires, pain records, bladder diaries, and physical examinations, including pain mapping and urinalysis. Further assessments encompass ultrasound, uroflowmetry, urethrocystoscopy, flow-electromyography, urodynamics, provocation tests (e.g., KCl test), bladder hydrodistension, and anesthesia-assisted bladder biopsy with mast cell counting. Potential differential diagnoses span musculoskeletal, gastrointestinal, gynecological, neurological, psychological, and urological disorders. Treatment for IC is primarily symptomatic, spanning non-invasive behavioral approaches, oral medications, complementary therapies, intravesical therapy, transurethral procedures, invasive or surgical interventions, and rehabilitation measures. A personalized, phased approach is recommended, reserving cystectomy and urinary diversion as a last resort, albeit yielding excellent pain relief in IC patients. IC severely impacts the overall quality of life, affecting physical, psychological, domestic, social, sexual, and occupational facets. It's a chronic and often recurring or progressively worsening condition, typically resulting in a low-capacity bladder, frequent urination, and severe pain.

·       Interstitial cystitis (IC) affects many individuals in the United States, with estimates ranging between 3 and 8 million women and 1 and 4 million men. It predominantly affects women and becomes more prevalent with age.

 

Thelansis’s “Interstitial Cystitis (IC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Interstitial Cystitis (IC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Interstitial Cystitis (IC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Interstitial Cystitis (IC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Interstitial Cystitis (IC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Interstitial Cystitis (IC), Interstitial Cystitis (IC) market outlook, Interstitial Cystitis (IC) competitive landscape, Interstitial Cystitis (IC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more